Asthma and allergic diseases are not risk factors for hospitalization in children with coronavirus disease 2019

Ann Allergy Asthma Immunol. 2021 May;126(5):569-575. doi: 10.1016/j.anai.2021.01.018. Epub 2021 Jan 23.

Abstract

Background: Coronavirus disease 2019 (COVID-19) emerged as a pandemic toward the end of 2019, causing large numbers of people to become infected and die.

Objective: To determine whether allergic diseases are a risk factor for hospitalization in COVID-19.

Methods: We conducted a study including 107 pediatric patients after COVID-19 recovery. The International Study of Asthma and Allergies in Childhood Phase 3 questionnaires were distributed together with a detailed history of environmental factors and an allergic evaluation including skin prick tests, specific immunoglobulin E tests, and spirometry. We investigated the prevalence of allergic diseases and evaluated the factors associated with hospitalization in COVID-19.

Results: A total of 61 (57%) patients were hospitalized and 46 (43%) patients were followed closely in the outpatient clinic. The prevalences of allergic rhinitis, asthma, atopic dermatitis, and episodic wheezing were 10.3%, 6,5%, 4.7%, and 3.7%, respectively, within the whole study population. Although having asthma with or without allergic rhinitis, atopic dermatitis, and passive tobacco exposure were not found to be related to hospitalization because of COVID-19, having a pet at home was found to decrease the risk of hospitalization (odds ratio, 0.191; 95% confidence interval, 0.047-0.779; P = .02). Spirometry tests revealed a higher forced expiratory volume in one second to forced vital capacity ratio and a peak expiratory flow reversibility in hospitalized patients than in nonhospitalized ones (P = .02 and P = .003, respectively).

Conclusion: Asthma and allergic diseases do not seem to be risk factors for hospitalization in children because of COVID-19, and having a pet at home can be a protective effect. Pulmonary function testing seems to be important for monitoring lung damage after COVID-19.

MeSH terms

  • Adolescent
  • Asthma / complications
  • Asthma / epidemiology*
  • COVID-19 / diagnosis
  • COVID-19 / epidemiology*
  • COVID-19 / pathology
  • Child
  • Child, Preschool
  • Coinfection / diagnosis
  • Coinfection / epidemiology*
  • Coinfection / pathology
  • Dermatitis, Atopic / complications
  • Dermatitis, Atopic / epidemiology*
  • Disease Susceptibility / pathology
  • Female
  • Forced Expiratory Volume / physiology
  • Hospitalization / statistics & numerical data
  • Humans
  • Infant
  • Male
  • Prospective Studies
  • Rhinitis, Allergic / complications
  • Rhinitis, Allergic / epidemiology*
  • Risk Factors
  • SARS-CoV-2
  • Severity of Illness Index
  • Surveys and Questionnaires
  • Tobacco Smoke Pollution / adverse effects
  • Treatment Outcome
  • Vital Capacity / physiology

Substances

  • Tobacco Smoke Pollution